Chryseobacterium/Elizabethkingia species infections in children

Abstract

Objective: To investigate the clinical and epidemiological features and outcome of Chryseobacterium and Elizabethkingia spp. infections in children, together with antimicrobial susceptibilities. Methods: This retrospective study was conducted at a tertiary pediatric hospital in Turkey. All patients infected with Chryseobacterium/Elizabethkingia spp. among those presenting to Ankara City Hospital between March 2014 and March 2022 were included. Results: A total of 49 cases were included and 29 cases were identified as Elizabethkingia. The median age was 14 (0.2-185.0) months. The majority (89.8%) of these patients had an underlying disease, including malignancy (42.9%). Bacteremia (46.9%) and central line-associated bloodstream infection (28.6%) were the most common infections. The thirty-day all-cause mortality rate was 12.2%. The most commonly used antibiotics were ciprofloxacin and trimethoprim-sulfamethoxazole (TMP-SMX). Forty-five (91.8%) isolates were susceptible to ciprofloxacin, 44 (91.6%) to TMP-SMX, and 21 (87.5%) to levofloxacin. Conclusions: Chryseobacterium and Elizabethkingia spp. are emergent, nosocomial pathogens and the majority of cases were older than the neonatal period. They were mainly seen in patients with long hospital stays, indwelling devices, and those who have received antibiotics within the last month, especially carbapenems. In addition, they were associated with bloodstream infection and malignancy. The most commonly useful antibiotics according to the resistance patterns were ciprofloxacin and TMP-SMX.

Keywords

Chryseobacterium / Elizabethkingia / Flavobacteriaceae / Weeksellaceae

References

[1] García-López M, Meier-Kolthoff JP, Tindall BJ, Gronow S, Woyke T, Kyrpides NC, et al. Analysis of 1 000 type-strain genomes improves taxonomic classification of Bacteroidetes. Front Microbiol 2019; 10:2083.

[2] Bender JM, Fisher RG. Elizabethkingia and Chryseobacterium species. In: Cherry J, Demmler-Harrison GJ, Kaplan SL, Steinbach WJ, et al, eds. Feigin and Cherry’s textbook of pediatric infectious diseases. 8th ed. Philadelphia, PA: Elsevier Saunders Company; 2018, p. 1132-1134.

[3] Dziuban EJ, Franks JL, So M, Peacock G, Blaney DD. Elizabethkingia in children: A comprehensive review of symptomatic cases reported from 1944 to 2017. Clin Infect Dis 2018; 67(1):144-149.

[4] Cooper S, Levy I, Ben-Zvi H, Ashkenazi-Hoffnung L, Ben-Shimol S, Shachor-Meyouhas Y, et al. Flavobacteriaceae bacteremia in children: A multicenter study. Pediatr Infect Dis J 2019; 38(11):1096-1099.

[5] Chen FL, Wang GC, Teng SO, Ou TY, Yu FL, Lee WS. Clinical and epidemiological features of Chryseobacterium indologenes infections: Analysis of 215 cases. J Microbiol Immunol Infect 2013; 46(6):425-432.

[6] Aykac K, Ozsurekci Y, Tuncer O, Sancak B, Cengiz AB, Kara A, et al. Six cases during 2012-2015 and literature review of Chryseobacterium indologenes infections in pediatric patients. Can J Microbiol 2016; 62(10):812-819.

[7] Dani A. Colonization and infection. Cent European J Urol 2014; 67:86-87.

[8] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315(8):801-810.

[9] Centers for Disease Control and Prevention (CDC). Identifying Healthcare Associated Infections (HAI) for NHSN Surveillance. [Online]. Available from:https://www.cdc.gov/nhsn/pdfs/pscmanual/2psc_identifyinghais_nhsncurrent.pdf. [Access on 18 October 2022].

[10] Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Twenty-fifth informational supplement M100-S25. Wayne, PA: CLSI; 2015, p. 54.

[11] Kirby JT, Sader HS, Walsh TR, Jones RN. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001). J Clin Microbiol 2004; 42(1):445-448.

[12] Aydin Teke T, Oz FN, Metin O, Bayhan GI, Gayretli Aydin ZG, Oguz M, et al. Chryseobacterium indologenes septicemia in an infant. Case Rep Infect Dis 2014; 2014:270521.

[13] Corbella M, Brandolini M, Cambieri P, Decembrino N, Pagani M, Bottazzi A, et al. A catheter-related bloodstream infection caused by Chryseobacterium indologenes successfully treated with antibiotic-lock rescue therapy. New Microbiol 2017; 40(3):223-225.

[14] Ceylan A, Güdücüoğlu H, Akbayram S, Bektaş A, Berktaş M. Sepsis caused by Chryseobacterium indologenes in a patient with hydrocephalus. Mikrobiyol Bul 2011; 45(4):735-740.

[15] Mehta R, Pathak A. Emerging Chryseobacterium indologenes infection in Indian neonatal intensive care units: A case report. Antibiotics (Basel) 2018; 7(4):109.

[16] Ceyhan M, Celik M. Elizabethkingia meningosepticum (Chryseobacterium meningosepticum) infections in children. Int J Pediatr 2011; 2011:215237.

[17] Alyami AM, Kaabia NM, AlQasim MA, Al Doghaim FS, Albehlal LB, Ahmed MA, et al. Chryseobacterium/Elizabethkingia species infections in Saudi Arabia. Saudi Med J 2020; 41(3):309-313.

[18] Srinivasan G, Muthusamy S, Raveendran V, Joseph NM, Easow JM. Unforeseeable presentation of Chryseobacterium indologenes infection in a paediatric patient. BMC Res Notes 2016; 12(9):212.

[19] Erinmez M, Büyüktas Manay A, Zer Y. Investigation of an outbreak of Elizabethkingia meningoseptica on a pediatric intensive care unit. GMS Hyg Infect Control 2021; 16:19.

[20] Chan JC, Chong CY, Thoon KC, Tee NWS, Maiwald M, Lam JCM, et al. Invasive paediatric Elizabethkingia meningoseptica infections are best treated with a combination of piperacillin/tazobactam and trimethoprim/sulfamethoxazole or fluoroquinolone. J Med Microbiol 2019; 68(8):1167-1172.

[21] Güngör S, Ozen M, Akinci A, Durmaz R. A Chryseobacterium meningosepticum outbreak in a neonatal ward. Infect Control Hosp Epidemiol 2003; 24(8):613-617.

[22] Wang L, Zhang X, Li D, Hu F, Wang M, Guo Q, et al. Molecular characteristics and antimicrobial susceptibility profiles of Elizabethkingia clinical isolates in Shanghai, China. Infect Drug Resist 2020; 13:247-256.

[23] Paul SP, Heaton PA. Chryseobacterium indologenes bacteraemia: A potential cause of early-onset neonatal sepsis in a full-term baby. J Coll Physicians Surg Pak 2022; 32(4):535-537.